摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methoxy-enanthic acid methyl ester | 36122-32-4

中文名称
——
中文别名
——
英文名称
2-methoxy-enanthic acid methyl ester
英文别名
2-Methoxy-oenanthsaeure-methylester;Methyl 2-methoxyheptanoate;methyl 2-methoxyheptanoate
2-methoxy-enanthic acid methyl ester化学式
CAS
36122-32-4
化学式
C9H18O3
mdl
——
分子量
174.24
InChiKey
VIOXFGXJURNMCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    224.3±13.0 °C(Predicted)
  • 密度:
    0.930±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    12
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability
    作者:John Pirsch、Ihor Bekersky、Flavio Vincenti、Garry Boswell、E. Steve Woodle、Ala Alak、Margaret Kruelle、Nancy Fass、David Facklam、Qais Mekki
    DOI:10.1177/00912700022009143
    日期:2000.5
    The tolerance and pharmacokinetics (PK) of tacrolimus (T) by the addition of mycophenolate mofetil (MMF) in stable kidney transplant patients (6/group) on long-term tacrolimus-based therapy were investigated. Patients received combination T and MMF therapy at three MMF doses: 1, 1.5, and 2 g/day administered twice daily. A 12-hour blood PK profile for T was obtained prior to MMF dosing; concomitant 12-hour profiles for T, mycophenolic acid (MPA), and mycophenolic acid glucuronide (MPAG) were obtained after 2 weeks of administration. Tolerance was monitored through 3 months. The intra- and intergroup PK of T were variable. The mean AUC0–12 of T for each group was increased after 2 weeks of concomitant MMF administration, but the increase was not statistically significant. Both drugs were well tolerated. Gastrointestinal events were of interest as such have been attributed to both T and MMF. Events reported were diarrhea, nausea, dyspepsia, and vomiting. Other common adverse events were headache, hypomagnesemia, and tremors. Most were mild, although a few were considered to be moderate. There was no apparent relationship between the incidence of any adverse event and MMF treatment group. In the present study, the coadministration of T and MMF did not significantly alter T pharmacokinetics.
    研究了长期接受他克莫司治疗的稳定肾移植患者(6 人/组)在他克莫司(T)基础上添加霉酚酸酯(MMF)的耐受性和药代动力学(PK)。患者在三种 MMF 剂量下接受 T 和 MMF 联合疗法:每天 1 克、1.5 克和 2 克,每天给药两次。在 MMF 给药前检测 T 的 12 小时血液 PK 曲线;给药 2 周后检测 T、霉酚酸 (MPA) 和霉酚酸葡萄糖醛酸苷 (MPAG) 的同时 12 小时曲线。对耐受性的监测持续了 3 个月。T的组内和组间PK各不相同。同时服用 MMF 2 周后,各组 T 的平均 AUC0-12 均有所增加,但增加幅度无统计学意义。两种药物的耐受性均良好。由于 T 和 MMF 均可引起胃肠道事件,因此胃肠道事件值得关注。报告的事件有腹泻、恶心、消化不良和呕吐。其他常见的不良反应有头痛、低镁血症和震颤。大多数不良反应是轻微的,但也有少数被认为是中度的。任何不良反应的发生率与 MMF 治疗组之间均无明显关系。在本研究中,同时服用 T 和 MMF 不会显著改变 T 的药代动力学。
  • SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS
    申请人:Theravance, Inc.
    公开号:EP1556372A2
    公开(公告)日:2005-07-27
  • [EN] SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS<br/>[FR] 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE SUBSTITUEE ET COMPOSES ASSOCIES
    申请人:THERAVANCE INC
    公开号:WO2004041806A2
    公开(公告)日:2004-05-21
    This invention provides 4-amino-1-(pyridylmethyl) piperidine of formula (I) and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.
  • Darzens; Levy, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1933, vol. 196, p. 187
    作者:Darzens、Levy
    DOI:——
    日期:——
查看更多